Performance Evaluation of the VIDAS TB-IGRA Assay.

CompletedOBSERVATIONAL
Enrollment

2,401

Participants

Timeline

Start Date

December 5, 2019

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Active TuberculosisLatent Tuberculosis InfectionNon-Tuberculous Mycobacterial (NTM) Pneumonia
Interventions
DIAGNOSTIC_TEST

Blood draw and IGRA test

One to two blood samples will be obtained from participants in all arms in order to conduct testing.

Trial Locations (24)

32610

University of Florida, Gainesville

60612

University of Illinois- Chicago, Chicago

63103

Saint Louis University, St Louis

80206

Naional Jewish Health, Denver

92103

UC San Diego, San Diego

94304

Stanford University, Palo Alto

07103

Rutgers University, Newark

Unknown

Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande

Universidade Federal Da Grande Dourados (UFGD), Dourados

Anti-TB center of Chambéry, Chambéry

Lapeyronie Hospital, Montpellier

Anti-TB center of Nanterre, Nanterre

Avicenne Hospital, Paris

Lariboisière Hospital, Paris

North Hospital, Saint-Etienne

National Center for Tuberculosis and Lung Disease, Tbilisi

Hinduja Hospital, Mumbai

INMI L. Spallanzani, Rome

Autonomous University of Baja California, Mexicali

TASK Applied Science, Delft Day Hospital Premises, Cape Town

University of Cape Town Centre for Lung Infection and Immunity, South Africa

Evelina London Children's Hospital, London

Royal Free Hospital, London

St Thomas' Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BioMérieux

INDUSTRY